PRODUCT INTRODUCTION
Adbiron 250mg Tablet is a medication primarily composed of Adbiron, a potent antiviral agent. It belongs to the class of nucleoside reverse transcriptase inhibitors (NRTIs), which are crucial in the management of HIV/AIDS. Adbiron works by inhibiting the enzyme reverse transcriptase, which is essential for the replication of HIV, thus reducing the viral load in the body. Adbiron 250mg Tablet is formulated to provide convenient dosing for patients, aiding in adherence to treatment regimens.
USES OF Adbiron 250mg Tablet
Adbiron 250mg Tablet is prescribed for the treatment of Human Immunodeficiency Virus (HIV) infection, both in adults and pediatric patients. It is often used in combination with other antiretroviral medications as part of highly active antiretroviral therapy (HAART) to suppress viral replication, improve immune function, and slow the progression of HIV-related illnesses.
BENEFITS OF Adbiron 250mg Tablet
- Viral Load Suppression: Adbiron effectively reduces the amount of HIV virus in the bloodstream, helping to control the infection and prevent its progression to AIDS.
- Immune System Support: By lowering viral load, Adbiron helps to preserve and improve immune function, reducing the risk of opportunistic infections and HIV-related complications.
- Long-term Management: When used as part of a comprehensive antiretroviral regimen, Adbiron can help individuals with HIV achieve and maintain long-term viral suppression, enabling them to lead healthier lives.
- Reduced Transmission Risk: Effective HIV treatment with Adbiron can significantly reduce the risk of transmitting the virus to others, contributing to HIV prevention efforts on a community level.
SIDE EFFECTS OF Adbiron 250mg Tablet
While Adbiron is generally well-tolerated, some individuals may experience side effects, including:
- Nausea
- Headache
- Diarrhea
- Fatigue
- Insomnia
- Rash
- Liver toxicity (rare) It is essential for patients to discuss any side effects with their healthcare provider, as some may require medical attention or adjustment of treatment.
References
-
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 4-5.
-
Abiraterone acetate. High Wycombe, Buckinghamshire: Janssen-Cilag Ltd.; 2017. [Accessed 26 Mar. 2019] (online) Available from:
-
Abiraterone Acetate. Patheon Inc.: Mississauga, Canada; 2011 [revised May 2016]. [Accessed 26 Mar. 2019] (online) Available from:
-
Central Drugs Standard Control Organisation (CDSCO). [Accessed 27 Mar. 2019] (online) Available from:
-
Abiraterone acetate [Prescribing Information]. Toronto, Canada: Patheon Inc.; 2011. [Accessed 20 Feb. 2024] (online) Available from:Â
Reviews
There are no reviews yet.